Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ALENDRONATE

All products: general benefit

Other products in the same Health Canada class (M05B, M05BA) — coverage varies; not interchangeable

  • Risedronate (Actonel DR): general benefit, Not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, Not a benefit
  • Etidronate (Didronel): limited Use 236, 237, Not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, Not a benefit
  • Pamidronate (Aredia): not a benefit
  • Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Fosamax · DIN 02245329 · 70mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fosamax · DIN 02245329 Manufacturer: Organon Canada Inc.; listing date 2003-01-30 Health Canada: Marketed since 2022-05-03 · brand FOSAMAX · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.7804 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69356 · Verify on the e-Formulary ↗ (DIN 02245329)

Source record
DIN 02245329: Fosamax Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id OCI Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $12.6250; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245329 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69356
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (10) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FOSAMAX® (alendronate sodium) is indicated for: • The treatment of osteoporosis in postmenopausal women. o For the treatment of osteoporosis in postmenopausal women, FOSAMAX® increases bone mass and prevents fractures, including those of the hip and spine (vertebral compression fractures). • The treatment of osteoporosis in men. o For the treatment of osteoporosis in men, FOSAMAX® increases bone mass and reduces the incidence of fractures. • The prevention of osteoporosis in postmenopausal women1 o For the prevention of osteoporosis, alendronate sodium may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. • The treatment and prevention of glucocorticoid-induced osteoporosis in men and women.1 o Alendronate sodium is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. 1 Although alendronate tablets 5 mg, 10 mg, a… https://pdf.hres.ca/dpd_pm/00071922.PDF PM date: not printed or not captured Source product: FOSAMAX; DIN 02245329; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.